首页> 外文期刊>Bone marrow transplantation >Peripheral blood stem cell transplantation in children with beta-thalassemia.
【24h】

Peripheral blood stem cell transplantation in children with beta-thalassemia.

机译:β地中海贫血患儿的外周血干细胞移植。

获取原文
获取原文并翻译 | 示例
           

摘要

Fifteen patients with beta-thalassemia received an allogeneic peripheral blood stem cell transplant. Median age was 3.5 years (1-15 years). Six were class I, four class II and five class III according to the Pesaro criteria. All of the donors were HLA-phenotypically identical (13 siblings and two parents). Nine patients were given BU + CY and six BU + CY plus ATG as conditioning. All patients received MTX (+1, +3, +6) and CsA (9-12 months) post transplant for GVHD prophylaxis. The median neutrophil and platelet engraftment times were day 12 and day 16, respectively. cGVHD was observed in three patients. Two patients died. Thirteen patients are well, and transfusion-independent 2-30 months after PSCT. No recurrences of thalassemia have been seen. Overall and event-free survival were 86.6%. In conclusion, we suggest that PSCT can be considered a safe and effective treatment for children with beta- thalassemia.
机译:15例地中海贫血患者接受了异基因外周血干细胞移植。中位年龄为3.5岁(1-15岁)。根据Pesaro标准,其中六个是I类,四个II类和五个III类。所有的供体在表型上都相同(13个兄弟姐妹和两个父母)。 9名患者接受了BU + CY和6 BU + CY加ATG的调理。移植后所有患者均接受MTX(+ 1,+ 3,+ 6)和CsA(9-12个月)预防GVHD。中性粒细胞和血小板植入时间的中位数分别是第12天和第16天。在三名患者中观察到了cGVHD。两名患者死亡。 13例患者健康,PSCT后2-30个月不依赖输血。没有发现地中海贫血的复发。总体生存率和无事件生存率为86.6%。总之,我们建议PSCT可被视为治疗β地中海贫血的一种安全有效的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号